Public Consultation on the Implementation of the Second European and Developing Countries Clinical Trials Partnership programme during the period 2014-2016

Fields marked with * are mandatory.

Introduction

This questionnaire is part of an interim evaluation of the implementation of the second European and Developing Countries Clinical Trials Partnership programme (EDCTP2). The European Commission is conducting this evaluation in order to develop recommendations about the future direction of the programme. The results of the evaluation will also be included in the interim evaluation of the EU's overall research programme Horizon 2020.

The purpose of this questionnaire is to gather views from a variety of stakeholders on the first three years (2014-2016) of the implementation of the EDCTP2 programme. The objective of the interim evaluation is to assess the implementation of the EDCTP2 programme since its launch in December 2014 up to the present moment; to judge how recommendations from previous evaluations of the EDCTP1 programme (2003-2013) have been implemented; and to provide an outlook on what can be expected from the EDCTP2 programme in the future. The success of this evaluation is to a large extent dependent upon the data, information and feedback we are able to gather among stakeholders of the EDCTP2 programme. Your input and opinion are of great value to the EDCTP2 programme and its future direction. Therefore we would be very grateful if you could take some time to fill in this short questionnaire.

The survey takes about 15 minutes and includes the following sections:

- Personal Information
- Advocacy and Communication
- Progress towards EDCTP2's Objectives
- Governance and Management
- Overall Assessment and Recommendations
Do you agree to your contribution being published under your name or the name of your organisation?

- I want my contribution to be published under my name
- I want my contribution to be published under the name of my organisation
- I want my contribution to be published anonymously
- I do not want my contribution to be published

Your contribution consists of your response to questions where you choose to give written feedback, as well as your response to the final three questions of the survey, where you have the opportunity to comment on the strengths, weaknesses and future direction of the EDCTP2 programme. If you do consent to the publication of your contribution, it will be included in the final report on this public consultation either under your name, the name of your organisation or anonymously. The final report will be made publicly accessible on the European Commission website. Your personal data and replies are recorded in a secured and protected database hosted by the Data Centre of the European Commission. The information provided by you will remain in the database until the results have been analysed or until one year after the end of the consultation. Note that whatever option is chosen, your contribution may still be subject to requests for 'access to documents' under Regulation 1049/2001.

In the interests of transparency, organisations are invited to provide the public with relevant information about themselves by registering in the Interest Representative Register and subscribing to its Code of Conduct. If the organisation is not registered, the submission is published separately from the registered organisations.

Background Information on EDCTP2

The first European and Developing Countries Clinical Trials Partnership (EDCTP) programme was launched in 2003 by the European Union (EU) and 15 European countries in response to the global health crisis caused by the three main poverty-related diseases: HIV/AIDS, malaria and tuberculosis. This was done with the aim to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics for these diseases. In its approach the first EDCTP programme (EDCTP1) focused on clinical trials in sub-Saharan Africa. Following the success of the EDCTP1 programme, the EU decided in 2014 to extend its commitment to this strategic partnership and increase its contribution from EUR 200 million for EDCTP1 (2003-2013) to EUR 683 million for EDCTP2 (2014-2024).

The general objective of the EDCTP2 programme is to contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for poverty-related and neglected diseases in partnership with countries in sub-Saharan Africa.

Section 1: Personal Information
* Please enter your first name:

* Please enter your surname:

* Please enter your e-mail address:

* Please enter the name of your organisation:

* At what type of organisation do you work (or study)?

  - Government administration
  - Non-governmental organisation
  - Inter-governmental organisation (e.g. African Union Commission, World Health Organization)
  - Large pharmaceutical company
  - Small or medium-sized enterprise (SME ≤ annual turnover of € 50 m; and staff of ≤ 250)
  - Other for-profit organisation (e.g. consultancies)
  - Private non-profit organisation
  - University / research institute

* Where is your organisation based?

  - Other
  - Algeria
  - Angola
  - Austria
  - Belgium
  - Benin
  - Botswana
  - Bulgaria
  - Burkina Faso
Burundi
Cabo Verde
Cameroon
Central African Republic
Chad
Comoros
Congo, Democratic Republic of the
Congo, Republic of the
Cote d'Ivoire
Croatia
Cyprus
Czech Republic
Denmark
Djibouti
Egypt
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Finland
France
Gabon
Gambia
Germany
Ghana
Greece
Guinea
Guinea-Bissau
Hungary
Iceland
Ireland
Israel
Italy
Kenya
Latvia
Lesotho
Liberia
Libya
Lithuania
Luxembourg
Madagascar
Malawi
Mali
Malta
Mauritania
Mauritius
Morocco
Mozambique
Namibia
Netherlands
Niger
Nigeria
Norway
Poland
Portugal
Romania
Rwanda
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
Slovak Republic
Slovenia
Somalia
South Africa
South Sudan
Spain
Sudan
Swaziland
Sweden
Switzerland
Tanzania
Togo
Tunisia
Turkey
Uganda
United Kingdom
Zambia
Zimbabwe

Other country, please specify:
What is the nature of your involvement with the EDCTP2 programme? (Multiple selections possible)

- I am a member of the EDCTP Scientific Advisory Committee
- I am a member of the EDCTP General Assembly
- I/my organisation has applied for funding from EDCTP1 and/or EDCTP2
- I/my organisation has been funded by EDCTP1 and/or EDCTP2
- No involvement
- Other type of involvement

Please specify:

What is your nationality?

- Other
- Algeria
- Angola
- Austria
- Belgium
- Benin
- Botswana
- Bulgaria
- Burkina Faso
- Burundi
- Cabo Verde
- Cameroon
- Central African Republic
- Chad
- Comoros
- Congo, Democratic Republic of the
- Congo, Republic of the
- Cote d'Ivoire
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Djibouti
Section 2: Advocacy and Communication

Please indicate whether or not you agree with the following statements about the quality of EDCTP2's advocacy and communication activities.

* Overall, EDCTP2's communication activities are relevant and of good quality.

○ Agree
○ Disagree
○ Don't know
EDCTP2’s advocacy activities contributed to expand and strengthen relationships between countries in sub-Saharan Africa and in Europe.

- Agree
- Disagree
- Don’t know

The EDCTP2 programme is a relevant and visible initiative for the global health research community worldwide.

- Agree
- Disagree
- Don’t know

The EDCTP2 programme is a relevant and visible initiative for health researchers in sub-Saharan Africa.

- Agree
- Disagree
- Don’t know

The EDCTP2 programme is a relevant and visible initiative for other public health stakeholders in sub-Saharan Africa.

- Agree
- Disagree
- Don’t know

The EDCTP2 programme is a relevant and visible initiative for health researchers in Europe.

- Agree
- Disagree
- Don’t know
In your opinion, how would you rate the quality of EDCTP2's different communication activities?

<table>
<thead>
<tr>
<th></th>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Call announcements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Applicant/grantee support</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Stakeholder meetings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*The EDCTP forum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Newsletters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Annual reports</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Section 3: Progress towards EDCTP2's Objectives

Please indicate whether or not you agree with the following statements about EDCTP2's progress towards its overall objectives.

*EDCTP2 is contributing to strengthening the capacity of sub-Saharan African countries to conduct clinical trials.

- Agree
- Disagree
- Don't know

*EDCTP2 is contributing to the integration of national programmes and has thereby increased the cost-effectiveness of European public investments.

- Agree
- Disagree
- Don't know
EDCTP2 is contributing to increasing the number of new or improved medical interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related and neglected diseases.

- Agree
- Disagree
- Don't know

EDCTP2 is contributing to the development of guidelines for improving or extending the use of existing medical interventions.

- Agree
- Disagree
- Don't know

The funding priorities of the EDCTP2 programme reflect the needs of sub-Saharan African countries.

- Agree
- Disagree
- Don't know

If you selected disagree, please briefly explain why.

As far as you know, have joint calls and/or other activities with public and private funders been launched under the EDCTP2 programme?

- Yes
- No
- Don't know

If you selected yes, please cite one example of how EDCTP2 has worked with other public or private funders.
As far as you know, have actions been taken under the EDCTP2 programme to increase its impact by effectively cooperating with other relevant European Union initiatives, including its development assistance programmes?

- Yes
- No
- Don't know

If you selected yes, please cite one example of how EDCTP2 has cooperated with other European Union initiatives.

In your opinion, how would you rate EDCTP2's activities to strengthen cooperation between European and sub-Saharan African countries?

<table>
<thead>
<tr>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Section 4: Governance and Management

Overall, how would you rate the management and execution of the EDCTP2 programme?

<table>
<thead>
<tr>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Overall, how would you rate the strategy and processes for setting EDCTP2's funding priorities?

<table>
<thead>
<tr>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In your opinion, how would you rate EDCTP2's funding mechanisms to support clinical trials research in sub-Saharan Africa?

<table>
<thead>
<tr>
<th></th>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In your opinion, how would you rate EDCTP2's funding mechanisms to strengthen the capacities of sub-Saharan African countries to conduct clinical trials?

<table>
<thead>
<tr>
<th></th>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In your opinion, how would you rate the quality and transparency of EDCTP2's proposal evaluation and selection process?

<table>
<thead>
<tr>
<th></th>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In your opinion, how would you rate the effectiveness of EDCTP2's proposal, submission and grant management tools?

<table>
<thead>
<tr>
<th></th>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In your opinion, how would you rate the effectiveness of EDCTP2's policies to prevent conflicts of interest?

<table>
<thead>
<tr>
<th></th>
<th>very poor</th>
<th>poor</th>
<th>fair</th>
<th>good</th>
<th>very good</th>
<th>don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
As far as you know, have recommendations from the 2009 evaluation of EDCTP1 been successfully implemented? (For reference purposes, you can find the 2009 Evaluation Report of EDCTP1 [here](#)).

- Yes
- No
- Don't know

If you selected yes, please cite one example of a change that was made based on recommendations from previous evaluations.

Section 5: Overall Assessment and Recommendations

Please assess the EDCTP2 programme during the period 2014-2016 in terms of key strengths:

Please assess the EDCTP2 programme during the period 2014-2016 in terms of weaknesses or opportunities for improvement:

Please provide specific recommendations about the future direction of the EDCTP2 programme:

Final remarks
Thank you very much for participating in this survey.

If you have any questions regarding this survey please do not hesitate to contact us at:
RTD-INFECTIOUS-DISEASES-PUBLIC-HEALTH@ec.europa.eu

Legal basis of the interim evaluation of the EDCTP2 programme

In accordance with EU decision 556/2014, the European Commission has to carry out, with the assistance of independent experts, an interim evaluation of the EDCTP2 programme by 30 June 2017. It further specifies that the European Commission has to deliver a report on the EDCTP2 interim evaluation to the European Parliament and to the Council by 31 December 2017. EU decision 556/2014 and all related legal documents, on which the EDCTP2 Programme is based can be found here.